Casgevy Expands to Children Age Two
FDA expanded Casgevy to patients aged two years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia, lowering the prior age threshold from 12 years. The July 1 approval…
